Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This is a phase I prospective study with the primary objective to compare the efficacy and
safety of Surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
in treatment of recurrent ovarian, primary peritoneal or fallopian tube cancers. Eligible
patients consenting to this protocol will undergo their scheduled surgical procedure. After
surgical cytoreduction to a residual disease ≤ 2.5 mm, a single dose of carboplatin (800
mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using
the closed-abdomen. HIPEC will be continued for 90 minutes in the hyperthermic phase
(41°C-43°C). At 4-6 weeks after CRS, patients will go on to receive 6 cycles of standard IV
platinum-based chemotherapy. The proportion of patients who are without evidence of
recurrence will be assessed at 6, 9, 12 and 18 months after the day of surgery.